Display options
Cite
Ankrah AO, Glaudemans AWJM, Klein HC, et al. The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nucl Med Mol Imaging. 2016;51(2):127-139doi: 10.1007/s13139-016-0422-0.
Ankrah, A. O., Glaudemans, A. W. J. M., Klein, H. C., Dierckx, R. A. J. O., & Sathekge, M. (2017). The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nuclear medicine and molecular imaging, 51(2), 127-139. https://doi.org/10.1007/s13139-016-0422-0
Ankrah, Alfred O, et al. "The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases." Nuclear medicine and molecular imaging vol. 51,2 (2017): 127-139. doi: https://doi.org/10.1007/s13139-016-0422-0
Ankrah AO, Glaudemans AWJM, Klein HC, Dierckx RAJO, Sathekge M. The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nucl Med Mol Imaging. 2017 Jun;51(2):127-139. doi: 10.1007/s13139-016-0422-0. Epub 2016 May 25. PMID: 28559937; PMCID: PMC5429294.
Copy Download .nbib Format: NLM
Share it on

Nucl Med Mol Imaging. 2017 Jun;51(2):127-139. doi: 10.1007/s13139-016-0422-0. Epub 2016 May 25.

The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases.

Nuclear medicine and molecular imaging

Alfred O Ankrah, Andor W J M Glaudemans, Hans C Klein, Rudi A J O Dierckx, Mike Sathekge

Affiliations

  1. Department of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, Private Bag X169, Pretoria, 0001 South Africa.
  2. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  3. Department of Psychiatry, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

PMID: 28559937 PMCID: PMC5429294 DOI: 10.1007/s13139-016-0422-0

Abstract

Human immune deficiency virus (HIV) is a leading cause of death. It attacks the immune system, thereby rendering the infected host susceptible to many HIV-associated infections, malignancies and neurocognitive disorders. The altered immune system affects the way the human host responds to disease, resulting in atypical presentation of these disorders. This presents a diagnostic challenge and the clinician must use all diagnostic avenues available to diagnose and manage these conditions. The advent of highly active antiretroviral therapy (HAART) has markedly reduced the mortality associated with HIV infection but has also brought in its wake problems associated with adverse effects or drug interaction and may even modulate some of the HIV-associated disorders to the detriment of the infected human host. Nuclear medicine techniques allow non-invasive visualisation of tissues in the body. By using this principle, pathophysiology in the body can be targeted and the treatment of diseases can be monitored. Being a functional imaging modality, it is able to detect diseases at the molecular level, and thus it has increased our understanding of the immunological changes in the infected host at different stages of the HIV infection. It also detects pathological changes much earlier than conventional imaging based on anatomical changes. This is important in the immunocompromised host as in some of the associated disorders a delay in diagnosis may have dire consequences. Nuclear medicine has played a huge role in the management of many HIV-associated disorders in the past and continues to help in the diagnosis, prognosis, staging, monitoring and assessing the response to treatment of many HIV-associated disorders. As our understanding of the molecular basis of disease increases nuclear medicine is poised to play an even greater role. In this review we highlight the functional basis of the clinicopathological correlation of HIV from a metabolic view and discuss how the use of nuclear medicine techniques, with particular emphasis of F-18 fluorodeoxyglucose, may have impact in the setting of HIV. We also provide an overview of the role of nuclear medicine techniques in the management of HIV-associated disorders.

Keywords: FDG PET; HAART; HIV-associated infections; HIV-associated malignancies; HIV-associated neurocognitive disease; Nuclear medicine

References

  1. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 - PubMed
  2. Cancer. 2006 Jan 1;106(1):128-35 - PubMed
  3. AIDS. 2011 Jun 1;25(9):1235-7 - PubMed
  4. J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):56-63 - PubMed
  5. Nucl Med Commun. 2010 Apr;31(4):311-4 - PubMed
  6. AIDS. 2006 Aug 1;20(12):1645-54 - PubMed
  7. Int J STD AIDS. 1996 Aug-Sep;7(5):337-46 - PubMed
  8. Neuropsychol Rev. 2009 Jun;19(2):152-68 - PubMed
  9. Biomed Res Int. 2015;2015:615150 - PubMed
  10. Lancet. 2003 Sep 20;362(9388):959-61 - PubMed
  11. Hematol Oncol Clin North Am. 1996 Oct;10 (5):1125-34 - PubMed
  12. Clin Transl Imaging. 2016;4:57-72 - PubMed
  13. Jpn J Radiol. 2010 Dec;28(10):759-62 - PubMed
  14. Blood. 2014 Nov 20;124(22):3201-11 - PubMed
  15. Blood. 2000 Feb 15;95(4):1406-12 - PubMed
  16. PLoS Pathog. 2015 Jan 29;11(1):e1004568 - PubMed
  17. Semin Nucl Med. 2002 Jan;32(1):47-59 - PubMed
  18. Nucl Med Commun. 2014 Aug;35(8):792-6 - PubMed
  19. J Nucl Med. 1993 Apr;34(4):567-75 - PubMed
  20. J Acquir Immune Defic Syndr. 2010 Aug;54(4):444-6 - PubMed
  21. Curr Opin Pulm Med. 2014 May;20(3):287-93 - PubMed
  22. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-189-94 - PubMed
  23. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6425-30 - PubMed
  24. HIV Med. 2013 Sep;14 (8):455-62 - PubMed
  25. Semin Nucl Med. 2013 Sep;43(5):349-66 - PubMed
  26. Clin Transl Imaging. 2016;4:131-144 - PubMed
  27. J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):180-7 - PubMed
  28. Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):640-7 - PubMed
  29. JAMA. 2012 Jul 25;308(4):379-86 - PubMed
  30. Curr Opin Infect Dis. 2006 Feb;19(1):14-9 - PubMed
  31. AIDS. 2010 Jun 1;24(9):1367-70 - PubMed
  32. Curr Opin Oncol. 2008 Sep;20(5):534-40 - PubMed
  33. J Intern Med. 2003 Mar;253(3):263-75 - PubMed
  34. J Clin Oncol. 2009 Feb 20;27(6):884-90 - PubMed
  35. Lancet Infect Dis. 2016 Jul;16(7):797-808 - PubMed
  36. HIV Med. 2004 Mar;5(2):67-73 - PubMed
  37. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10 ):1986-91 - PubMed
  38. JAMA. 2001 Apr 4;285(13):1736-45 - PubMed
  39. Ann Intern Med. 1996 Aug 15;125(4):257-64 - PubMed
  40. J Inflamm (Lond). 2012 Jun 22;9(1):26 - PubMed
  41. Mov Disord. 2007 Oct 15;22(13):1852-6 - PubMed
  42. AIDS. 2008 Aug 20;22(13):1589-99 - PubMed
  43. J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 - PubMed
  44. Ann Neurol. 1987 Dec;22(6):700-6 - PubMed
  45. Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1760-9 - PubMed
  46. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):164-71 - PubMed
  47. Br J Cancer. 2010 Jul 27;103(3):416-22 - PubMed
  48. AIDS. 2004 Dec 3;18(18):2430-2 - PubMed
  49. Lancet. 2003 Sep 20;362(9388):945-50 - PubMed
  50. J Nucl Med. 2006 Aug;47(8):1326-34 - PubMed
  51. Arch Neurol. 2012 Jan;69(1):72-7 - PubMed
  52. Science. 1994 Dec 16;266(5192):1865-9 - PubMed
  53. AIDS. 2006 Apr 24;20(7):985-93 - PubMed
  54. Semin Nucl Med. 1988 Oct;18(4):273-86 - PubMed
  55. J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 - PubMed
  56. Blood. 2004 Nov 15;104(10):3009-20 - PubMed
  57. Microbiol Rev. 1993 Mar;57(1):183-289 - PubMed
  58. Lancet. 1999 Jun 19;353(9170):2093-9 - PubMed
  59. J Clin Oncol. 1997 Sep;15(9):3085-92 - PubMed
  60. J Neurovirol. 2002 Dec;8 Suppl 2:115-21 - PubMed
  61. Nucl Med Commun. 2009 Oct;30(10 ):763-9 - PubMed
  62. HIV Med. 2005 Mar;6(2):66-78 - PubMed
  63. Eur J Neurol. 2006 Mar;13(3):283-91 - PubMed
  64. J Nucl Med. 1996 Jul;37(7):1133-41 - PubMed
  65. Drug Saf. 2000 Jul;23(1):57-76 - PubMed
  66. Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):648-52 - PubMed
  67. AIDS. 2009 Jan 2;23(1):41-50 - PubMed
  68. AJR Am J Roentgenol. 2011 Aug;197(2):284-94 - PubMed
  69. Curr Opin Oncol. 2009 Sep;21(5):420-4 - PubMed
  70. Blood. 2010 Dec 16;116(25):5600-4 - PubMed
  71. Acta Clin Belg. 2012 Jul-Aug;67(4):276-81 - PubMed
  72. Neurology. 2010 Jul 13;75(2):111-5 - PubMed
  73. Curr HIV Res. 2010 Oct;8(7):493-7 - PubMed
  74. Virology. 2000 Sep 1;274(2):255-61 - PubMed
  75. Nucl Med Commun. 2010 Feb;31(2):137-40 - PubMed
  76. Arch Neurol. 2000 Nov;57(11):1601-7 - PubMed
  77. Br J Haematol. 2005 Sep;130(5):662-70 - PubMed
  78. J Comput Assist Tomogr. 1995 Jul-Aug;19(4):532-6 - PubMed
  79. Transfus Apher Sci. 2011 Apr;44(2):167-72 - PubMed
  80. Recent Results Cancer Res. 2013;194:189-219 - PubMed
  81. Lancet. 1996 Jul 13;348(9020):99-106 - PubMed
  82. Pharm World Sci. 1998 Dec;20(6):253-7 - PubMed
  83. J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 - PubMed
  84. Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9 - PubMed
  85. Am J Surg Pathol. 2003 Dec;27(12):1546-50 - PubMed
  86. J Obstet Gynaecol. 2005 Oct;25(7):706-10 - PubMed
  87. Nat Med. 1996 Aug;2(8):918-24 - PubMed
  88. J Nucl Med. 2009 Apr;50(4):497-500 - PubMed
  89. J Nucl Med. 2014 Feb;55(2):308-14 - PubMed
  90. J Nucl Med. 1996 Oct;37(10 ):1662-7 - PubMed
  91. Am J Med. 2001 Dec 15;111(9):704-11 - PubMed
  92. J Nucl Med. 1997 Oct;38(10 ):1575-83 - PubMed
  93. J Neuropsychiatry Clin Neurosci. 1992 Summer;4(3):280-7 - PubMed
  94. Curr Clin Top Infect Dis. 1991;11:35-51 - PubMed
  95. Brain Res Bull. 2007 Apr 30;72 (2-3):148-51 - PubMed
  96. Curr Opin Oncol. 2010 Sep;22(5):449-55 - PubMed
  97. Curr HIV Res. 2004 Oct;2(4):343-9 - PubMed
  98. J Neural Transm (Vienna). 2010 Jun;117(6):699-705 - PubMed
  99. Gynecol Oncol. 2012 Oct;127(1):136-40 - PubMed
  100. Nucl Med Commun. 2009 Jan;30(1):41-7 - PubMed
  101. Lancet Oncol. 2009 Dec;10(12):1152-9 - PubMed
  102. Nucl Med Biol. 2007 Oct;34(7):737-42 - PubMed

Publication Types